Biologic Therapy and Novel Molecular Targets of Severe Asthma Amber N. Pepper, MD, Harald Renz, MD, Thomas B. Casale, MD, Holger Garn, PhD The Journal of Allergy and Clinical Immunology: In Practice Volume 5, Issue 4, Pages 909-916 (July 2017) DOI: 10.1016/j.jaip.2017.04.038 Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Figure 1 Biologic and novel therapies for the treatment of severe asthma. This figure includes only approved and emerging therapies with published human data. CRTH2, Chemoattractant receptor-homologous molecule expressed on TH2 cells; DP2, prostaglandin D2 receptor 2; IgE, immunoglobulin E; IL, interleukin; TSLP, thymic stromal lymphopoeitin. The Journal of Allergy and Clinical Immunology: In Practice 2017 5, 909-916DOI: (10.1016/j.jaip.2017.04.038) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions